Last reviewed · How we verify
Dexilant
At a glance
| Generic name | Dexilant |
|---|---|
| Also known as | Dexlansoprazole |
| Sponsor | Genuine Research Center, Egypt |
| Target | Sterile alpha and TIR motif-containing protein 1, Cytosolic endo-beta-N-acetylglucosaminidase, Potassium-transporting ATPase |
| Modality | Small molecule |
| Therapeutic area | Gastroenterology |
| Phase | FDA-approved |
Approved indications
- Erosive esophagitis
- Gastroesophageal reflux disease
- Maintenance of Healing Erosive Esophagitis
- Peptic ulcer
Common side effects
- Headaches
- Diarrhea
- Nausea
- Abdominal pain
- Vomiting
Serious adverse events
- Myocardial infarction
- GI ulcers and perforation
- Convulsion
- Hematemesis
- Hematochezia
Key clinical trials
- A Study to Check the Safety of Dexlansoprazole and Learn If it Can Heal Erosive Esophagitis (EE) and Keep it Healed in Children 2 to 11 Years Old (PHASE2)
- Prevalence of Asymptomatic H Pylori Infection Among Patients Undergoing PCI and Impact of Its Eradication on Occurrence of GIT Symptoms and Bleeding" (PHASE3)
- Randomized Active-Controlled Trial Evaluating Fexuprazan (Fexuclue Tab) for Prevention Upper Gastrointestinal Bleeding in High Bleeding Risk Patients Receiving Dual Antiplatelet Therapy After Coronary Intervention (NA)
- Helping Osteoarthritis Patients to Walk With NSAID (PHASE4)
- Fourteen-Day Vonoprazan-Based Dual Therapy With Amoxicillin as First-Line Helicobacter Pylori Treatment in Comparison With Extended Sequential Therapy (PHASE4)
- Routine Versus Symptomatic Protein Pump Inhibitor Therapy for Prevention of Gastroesophageal Reflux After Per Oral Endoscopic Myotomy for Esophageal Achalasia (NA)
- CURE-H. Pylori: A Trial on the Combination of Anti-Ulcerants and Levofloxacin-Based Therapy for Helicobacter Pylori Eradication (PHASE4)
- A Study to Check the Safety of Dexlansoprazole and Learn if it Can Treat Symptomatic Nonerosive Gastroesophageal Reflux Disease in Children 2 to 11 Years Old (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Dexilant CI brief — competitive landscape report
- Dexilant updates RSS · CI watch RSS
- Genuine Research Center, Egypt portfolio CI